Indeed, ERG is one of the most overexpressed oncogenes in prostate cancer, where a chromosomal translocation results in the fusion of the promoter region of androgen-regulated transmembrane protease serine 2 (TMPRSS2) with the DNA-binding domain of ERG [86]. Here, ERG is linked to prostate cancer.